HRP20030674A2 - Pharmaceutical dosage forms of epothilones for oral administration - Google Patents

Pharmaceutical dosage forms of epothilones for oral administration Download PDF

Info

Publication number
HRP20030674A2
HRP20030674A2 HR20030674A HRP20030674A HRP20030674A2 HR P20030674 A2 HRP20030674 A2 HR P20030674A2 HR 20030674 A HR20030674 A HR 20030674A HR P20030674 A HRP20030674 A HR P20030674A HR P20030674 A2 HRP20030674 A2 HR P20030674A2
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
alkyl
group
buffer
epothilone
Prior art date
Application number
HR20030674A
Other languages
English (en)
Croatian (hr)
Inventor
Bandyopadhyay Rebanta
Timothy
Panaggio Andrea
Krishnaswamy
Sailesh
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20030674A2 publication Critical patent/HRP20030674A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20030674A 2001-01-25 2002-01-25 Pharmaceutical dosage forms of epothilones for oral administration HRP20030674A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29001901P 2001-05-11 2001-05-11
PCT/US2002/002518 WO2002058701A1 (en) 2001-01-25 2002-01-25 Pharmaceutical dosage forms of epothilones for oral administration

Publications (1)

Publication Number Publication Date
HRP20030674A2 true HRP20030674A2 (en) 2005-06-30

Family

ID=26950349

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030674A HRP20030674A2 (en) 2001-01-25 2002-01-25 Pharmaceutical dosage forms of epothilones for oral administration

Country Status (26)

Country Link
US (2) US6576651B2 (cs)
EP (1) EP1361877A1 (cs)
JP (1) JP2004528287A (cs)
KR (1) KR20040025888A (cs)
CN (1) CN1268336C (cs)
AR (1) AR035078A1 (cs)
BG (1) BG108027A (cs)
BR (1) BR0206695A (cs)
CA (1) CA2434584A1 (cs)
CZ (1) CZ20032023A3 (cs)
EE (1) EE200300329A (cs)
HR (1) HRP20030674A2 (cs)
HU (1) HUP0303800A3 (cs)
IL (1) IL156759A0 (cs)
IS (1) IS6892A (cs)
MX (1) MXPA03006476A (cs)
NO (1) NO20033343L (cs)
NZ (1) NZ526871A (cs)
PE (1) PE20020853A1 (cs)
PL (1) PL368636A1 (cs)
RU (1) RU2291695C2 (cs)
SK (1) SK9212003A3 (cs)
TW (1) TWI250017B (cs)
UY (1) UY27138A1 (cs)
WO (2) WO2002058699A1 (cs)
YU (1) YU58103A (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
CA2374944A1 (en) 1999-06-10 2000-12-21 Nigel Hacker Spin-on-glass anti-reflective coatings for photolithography
US6824879B2 (en) 1999-06-10 2004-11-30 Honeywell International Inc. Spin-on-glass anti-reflective coatings for photolithography
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
EP1353667A1 (en) * 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
EE200300396A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
BRPI0207961B8 (pt) * 2001-03-14 2021-05-25 Bristol Myers Squibb Co uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
EP1472574A4 (en) 2001-11-15 2005-06-08 Honeywell Int Inc ANTI-REFLECTIVE COATINGS DESIGNED TO BE INSTALLED BY ROTATION FOR PHOTOLITHOGRAPHY
US7211593B2 (en) * 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
SI1767535T1 (sl) 2002-08-23 2010-03-31 Sloan Kettering Inst Cancer Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP2006504743A (ja) * 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド 治療製剤
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
DE202004021169U1 (de) * 2003-08-26 2007-03-01 Shire Holdings Ag Pharmazeutische Formulierung, die Lanthanverbindungen enthält
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
CA2545806C (en) 2003-11-14 2014-09-16 Brigham And Women's Hospital, Inc. Methods of modulating immunity
US8053159B2 (en) 2003-11-18 2011-11-08 Honeywell International Inc. Antireflective coatings for via fill and photolithography applications and methods of preparation thereof
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20060069136A1 (en) * 2004-09-24 2006-03-30 Ulrich Klar Use of Epothilones in the treatment of bone metastasis
DK1817013T3 (da) * 2004-11-18 2008-10-13 Brystol Myers Squibb Company Enterisk coatet kugle omfattende Ixabepilon
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8642246B2 (en) 2007-02-26 2014-02-04 Honeywell International Inc. Compositions, coatings and films for tri-layer patterning applications and methods of preparation thereof
CN104666297A (zh) 2008-04-24 2015-06-03 百时美施贵宝公司 埃坡霉素D在治疗包括阿尔茨海默病的τ相关疾病中的用途
US8557877B2 (en) 2009-06-10 2013-10-15 Honeywell International Inc. Anti-reflective coatings for optically transparent substrates
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
US8864898B2 (en) 2011-05-31 2014-10-21 Honeywell International Inc. Coating formulations for optical elements
CN102276433B (zh) * 2011-06-30 2016-04-20 南昌大学 木豆素c及其衍生物及其在制备抗癌药物中的应用
WO2016167892A1 (en) 2015-04-13 2016-10-20 Honeywell International Inc. Polysiloxane formulations and coatings for optoelectronic applications

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DK0903348T4 (da) 1995-11-17 2008-10-20 Biotechnolog Forschung Gmbh Epothilonderivater og fremstilling deraf
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
EA002400B1 (ru) * 1996-03-12 2002-04-25 Пи Джи-Ти Экс Эл Компани, Л.П. Водорастворимые пролекарства противоракового действия
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19636343C1 (de) * 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
ATE267197T1 (de) 1996-11-18 2004-06-15 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
CA2281105A1 (en) 1997-02-25 1998-09-03 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilones with a modified side chain
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
US6348551B1 (en) 1997-04-18 2002-02-19 Studiengesellschaft Kohle Mbh Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
AU8542898A (en) 1997-07-16 1999-02-10 Schering Aktiengesellschaft Thiazole derivatives, method for their production and use
EP1847540A1 (de) 1997-08-09 2007-10-24 Bayer Schering Pharma Aktiengesellschaft Neue Epothilonderivate, Herstellungsverfahren dafür und ihre pharmazeutische Verwendung
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
WO1999039694A2 (en) 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
EP1058679B1 (en) 1998-02-25 2005-10-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
CN1122668C (zh) 1998-12-22 2003-10-01 诺瓦提斯公司 环氧噻酮衍生物，其制备方法及其药物组合物
BR0008331A (pt) 1999-02-18 2002-01-29 Schering Ag Derivados de 16-halogeno-epotilon, processos para a sua preparação e seu emprego farmacêutico
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
MXPA03006412A (es) 2001-01-25 2003-10-15 Bristol Myers Squibb Co Metodos para administrar analogos de epotilona para tratamiento de cancer.
BRPI0207961B8 (pt) 2001-03-14 2021-05-25 Bristol Myers Squibb Co uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.

Also Published As

Publication number Publication date
CN1498106A (zh) 2004-05-19
NO20033343L (no) 2003-09-24
UY27138A1 (es) 2002-08-30
IL156759A0 (en) 2004-02-08
TWI250017B (en) 2006-03-01
BG108027A (bg) 2004-12-30
HUP0303800A3 (en) 2005-02-28
AU2002253880B2 (en) 2006-11-09
CZ20032023A3 (cs) 2005-03-16
EP1361877A1 (en) 2003-11-19
US20020177615A1 (en) 2002-11-28
AR035078A1 (es) 2004-04-14
SK9212003A3 (en) 2004-11-03
RU2291695C2 (ru) 2007-01-20
USRE40387E1 (en) 2008-06-17
CA2434584A1 (en) 2002-08-01
MXPA03006476A (es) 2003-09-22
YU58103A (sh) 2006-03-03
JP2004528287A (ja) 2004-09-16
NZ526871A (en) 2006-01-27
EE200300329A (et) 2003-10-15
US6576651B2 (en) 2003-06-10
RU2003126174A (ru) 2005-02-27
HUP0303800A2 (hu) 2004-03-29
NO20033343D0 (no) 2003-07-24
IS6892A (is) 2003-07-24
PE20020853A1 (es) 2002-09-27
WO2002058701A1 (en) 2002-08-01
BR0206695A (pt) 2004-04-20
PL368636A1 (en) 2005-04-04
KR20040025888A (ko) 2004-03-26
CN1268336C (zh) 2006-08-09
WO2002058699A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
HRP20030674A2 (en) Pharmaceutical dosage forms of epothilones for oral administration
ZA200305536B (en) Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones.
US6936628B2 (en) Oral administration of epothilones
ES2304240T3 (es) Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
RS58203B1 (sr) Pirolobenzodiazepini i njihovi konjugati
US7053069B2 (en) Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
AU2002245296B2 (en) Methods of administering epothilone analogs for the treatment of cancer
RS58103B1 (sr) Bežični video sistem za model lokomotiva
AU2002253880C1 (en) Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones
AU2002253880A1 (en) Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20061228

Year of fee payment: 6

ODBI Application refused